Awards for export achievement were granted to the company in 1990, 1993, 1997 and the Queen's award for enterprise in 2001; this year it is the award for enterprise and international trade
The Queen's award is a coveted commercial prize and is a testimony to the hard work and dedication of Randox in the global diagnostics market.
Randox Laboratories is the only company in Northern Ireland to be awarded a Queen's award in 2007.
Randox is a privately owned international clinical diagnostics company, exporting 95% of all products to over 130 countries with offices in 26 countries worldwide.
Randox now manufactures 5% of the world's clinical chemistry products and now rank 23rd in the $20 billion global clinical diagnostics market.
Randox has a very strong R+D ethos with 200 R+D staff, reinvesting 20% of annual revenue to improve diagnostic tests.
Products cover a range of disease areas, including cancer, cardiovascular disease, diabetes and a range of applications including drugs of abuse, thyroid and fertility testing.
Randox Laboratories has invested over £75 million to develop the world's first automated protein biochip array platform and this innovative technology has proven to be the most revolutionary multi-analyte testing platform available today.
This reinforces Randox's mission statement to improve and revolutionise healthcare through continuously improving diagnostic solutions and has lead to the introduction of many novel tests.
One of the tests includes a novel diagnostic cardiovascular kit which significantly improves the early diagnosis of cardiac events.
The company develop, manufacture and market clinical diagnostic products worldwide.
Core products include biochip array technology; clinical chemistry analysers and reagents; quality controls and EQA; environmental diagnostics; recombinant proteins and antibodies.
Randox production facilities are FDA compliant and the company currently have more tests in development than any other diagnostic company in the world.
